Fig 1.
IL-6 mRNA was up-regulated after FAC treatment in BV2 cells.
BV2 microglial cells were treated with FAC for 24 h. Real-time PCR was used to detect IL-6 mRNA levels. IL-6 mRNA was up-regulated after FAC treatment compared with the untreated control. Each bar represents the mean ± S.E.M of 6 independent experiments (*P < 0.05 compared with the control; n = 6).
Fig 2.
Expression of IRP1, DMT1, and FPN1 in BV2 cells treated with IL-6.
A: Western blots to detect IRP1 expression. IRP1 expression was significantly increased in BV2 cells treated with IL-6. B: Western blots to detect DMT1 expression. DMT1 expression was significantly increased in BV2 cells treated with IL-6. C: Western blots to detect FPN1 expression. FPN1 expression was significantly decreased in BV2 cells treated with IL-6. All data are presented as the ratio of iron-related-proteins to β-actin. Each bar represents the mean ± S.E.M of 5 independent experiments (*P < 0.05 compared with control; n = 5).
Fig 3.
Phosphorylated JNK/total JNK ratios were increased in IL-6-treated BV2 cells.
A: Western blots to detect phosphorylated JNK and total JNK expression. Ratio of phosphorylated JNK/total JNK increased after IL-6 treatment for 1 h, compared with the control group. B: Statistical analysis. Data are presented as the ratio of P-JNK to total JNK. Each bar represents the mean ± S.E.M of 3 independent experiments (*P < 0.05 compared with the control; n = 3).
Fig 4.
Expression of IRP1, DMT1, and FPN1 in IL-6-treated BV2 cells was inhibited by SP600125 pretreatment.
A: Western blots to detect IRP1 expression. IRP1 expression was significantly increased in BV2 cells treated with IL-6. Pretreatment with SP600125 attenuated the up-regulation of IRP1. B: Western blots to detect DMT1 expression. DMT1 expression was significantly increased in BV2 cells treated with IL-6. Pretreatment with SP600125 attenuated the up-regulation of DMT1. C: Western blots to detect FPN1 expression. FPN1 expression significantly decreased in BV2 cells treated with IL-6. Pretreatment with SP600125 attenuated the down-regulation of FPN1. β-actin was used as a loading control. Data are presented as the ratio of protein to β-actin. Each bar represents the mean ± S.E.M of 4 independent experiments (*P < 0.05 compared with control, #P < 0.05 compared with IL-6 group; n = 4).
Fig 5.
Graphical representation of the mechanism by which iron load can increase IL-6 mRNA expression, and IL-6 can regulate iron related proteins in BV2 cells.
Iron load can increase IL-6 mRNA expression in BV2 cells. IL-6 up-regulates DMT1 expression and down-regulates FPN1 expression by IRP1 activation in BV2 microglial cells through JNK signaling pathways.